Thermo Fisher Scientific Inc. (TMO) Intrinsic Value & DCF Valuation
Medical - Diagnostics & Research · NYSE
Current Price
$570.47
Intrinsic Value
$672.51
+15.2% margin of safety
What Is Thermo Fisher Scientific Inc.'s Intrinsic Value?
As of 2026-07-30, the base-case DCF model estimates the intrinsic value of Thermo Fisher Scientific Inc. (TMO) at $672.51 per share, compared with a market price of $570.47, a margin of safety of +15.2%. The base case assumes 10.1% annual free cash flow growth and a 10.0% discount rate.
Across the sensitivity grid the estimate spans $562.85 to $797.01. Intrinsic value is an estimate built on assumptions, not a fact. A higher discount rate or slower growth pushes the estimate down, while stronger cash flow growth lifts it.
How the DCF works · Recalculate with your own assumptions · What is intrinsic value?
Is Thermo Fisher Scientific Inc. (TMO) Undervalued?
At $570.47, TMO trades about 15.2% below the base-case intrinsic value estimate. That is a real discount, but it stays short of the 30% margin of safety required before calling a stock undervalued.
COMPETITIVE MOAT
↑Broad Product Portfolio & Scale
Thermo Fisher offers an extensive range of scientific instruments, reagents, and services. This broad portfolio creates significant customer stickiness and operational efficiencies due to scale.
↑Ecosystem & Brand Reputation
The company has built a strong ecosystem of integrated solutions and a trusted brand. This fosters high switching costs for customers deeply embedded in their workflows and technologies.
↑Data & Innovation Leadership
Continuous investment in R&D and a vast installed base generate valuable data insights. This fuels ongoing innovation, particularly in areas like AI-enabled research, reinforcing their market position.
INVESTMENT RISKS
↓Regulatory Scrutiny & Compliance
The highly regulated nature of the medical diagnostics and research industry exposes Thermo Fisher to evolving compliance requirements. Changes in regulations could impact product development and market access.
↓Supply Chain Disruptions
Reliance on global supply chains for raw materials and components makes the company vulnerable to disruptions. Geopolitical events or natural disasters could impact production and delivery.
↓Technological Obsolescence
Rapid advancements in scientific technology could render existing products obsolete. Failure to innovate quickly enough could lead to a loss of competitive advantage.
Base case
TMO base case valuation
Intrinsic Value
$672.51
Margin of safety
+15.2%
Expected annual return
+3.3%
Base case assumptions: 10.1% annual growth, 10.0% discount rate, 29x exit multiple, 5 year projection. Data as of 2026-07-30.
This base case uses default assumptions and is not financial advice. The intrinsic value changes significantly when the growth rate or discount rate changes. Open the calculator to set your own assumptions and see the full sensitivity range.
Customize the TMO valuation
Adjust the growth rate, discount rate, and exit multiple to see how the intrinsic value and margin of safety for Thermo Fisher Scientific Inc. respond.
Open DCF Calculator for TMOCompany Overview
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company's products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts.
Financial Metrics — TMO Stock Valuation Data
Revenue/Share (TTM)
$124.89
FCF/Share (TTM)
$19.73
ROIC (TTM)
7.4%
ROE (TTM)
13.4%
P/FCF
29.0x
EV/EBITDA
22.9x
FCF Yield
3.45%
Debt/Equity
0.81x
Based on trailing twelve-month data, TMO shows a free cash flow per share of $19.73 and a ROIC of 7.4%, key inputs for stock valuation using the DCF method. The P/FCF ratio of 29.0x and FCF yield of 3.45% are important context metrics when evaluating TMO's stock valuation relative to peers.
Frequently Asked Questions
What is the intrinsic value of TMO?
Thermo Fisher Scientific Inc. currently generates $19.73 in free cash flow per share. At the current price of $570.47, a DCF model would discount these cash flows at an appropriate WACC and apply a terminal growth rate to arrive at an intrinsic value. The result depends heavily on your growth and discount rate assumptions — a 1% change in WACC typically shifts the fair value estimate by 10-15%. In MiniValuator the model uses a single discount rate that you can edit directly, 10% by default, rather than a computed WACC.
Is TMO undervalued?
TMO trades at a P/FCF ratio of 29.0x with a free cash flow yield of 3.45%. This P/FCF is in a moderate range. However, whether TMO is truly undervalued requires comparing the DCF intrinsic value to the current market price and evaluating whether the margin of safety is sufficient for your risk tolerance.
How do I value TMO stock using DCF?
To perform a DCF valuation on Thermo Fisher Scientific Inc.: (1) Start with the trailing free cash flow per share ($19.73) as the base, (2) project future FCF growth over 5-10 years based on Medical - Diagnostics & Research industry trends and company fundamentals, (3) apply a discount rate (WACC) reflecting TMO's risk profile — with a debt-to-equity of 0.81x, capital structure is an important factor, and (4) add a terminal value for cash flows beyond the projection period.
What is DCF valuation and how does it apply to TMO?
DCF (Discounted Cash Flow) estimates what a company is worth today based on its future cash generation. For Thermo Fisher Scientific Inc., this means projecting how much free cash flow the company will produce over the next 5-10 years, shaped by Medical - Diagnostics & Research trends, then discounting those amounts to today's dollars. TMO's ROIC of 7.4% means the company's return on invested capital sits below the level that typically clears its cost of capital.
How does WACC affect TMO stock valuation?
WACC (Weighted Average Cost of Capital) is the discount rate in a DCF model — it reflects the minimum return investors require. For TMO, with a debt-to-equity ratio of 0.81x, the capital structure directly influences WACC. A 1% increase in WACC typically reduces the intrinsic value by 10-15%. At an EV/EBITDA of 22.9x, the market's implied discount rate can be reverse-engineered for comparison. In MiniValuator you set this discount rate yourself as a single editable number, 10% by default, instead of computing a formal WACC.
Learn More
- See TMO PE Valuation → — Earnings-based stock valuation using PE ratio analysis
- DCF Methodology — Step-by-step guide to discounted cash flow analysis
- PE Methodology — Guide to PE ratio stock valuation
- WACC — Understanding the discount rate used in DCF
- Margin of Safety — How to evaluate downside protection
- Intrinsic Value — How to evaluate stock fair value
- How to Calculate Intrinsic Value — Complete guide for investors
Related Valuations
All Healthcare valuationsDCF and P/E value TMO with different methods and assumptions, so the two conclusions can differ. Compare the P/E fair value.
Price as of 2026-07-30. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.